PE20140934A1 - Derivados de pirazol - Google Patents
Derivados de pirazolInfo
- Publication number
- PE20140934A1 PE20140934A1 PE2013002748A PE2013002748A PE20140934A1 PE 20140934 A1 PE20140934 A1 PE 20140934A1 PE 2013002748 A PE2013002748 A PE 2013002748A PE 2013002748 A PE2013002748 A PE 2013002748A PE 20140934 A1 PE20140934 A1 PE 20140934A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- pirazole
- morfolin
- carboxamide
- derivatives
- Prior art date
Links
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 4
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- -1 3-CYANOPHENYL Chemical class 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REFERIDO A DERIVADOS DE PIRAZOL DE LA FORMULA IA DONDE R1 ES HIDROGENO, FENILO OPCIONALMENTE SUSTITUIDO POR HALOGENO, CN, ENTRE OTROS; R2 Y R3 SON HIDROGENOS O ALQUILOS INFERIORES; Z ES UN ENLACE -CH2-, -O-. SON COMPUESTOS PREFERIDOS (S)-N-(4-(MORFOLIN-2-IL) FENIL)-5-FENIL-1H-PIRAZOL-3-CARBOXAMIDA, (S)- 1- METIL-N-(4-(MORFOLIN-2-IL) FENIL)- 5-FENIL-1H-PIRAZOL-3-CARBOXAMIDA, (S)-5-(3-CIANOFENIL)-N-(4-(MORFOLIN-2-IL) FENIL)-1H-PIRAZOL-3-CARBOXAMIDA, ENTRE OTROS. REFERIDO TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO COMPUESTO Y UN VEHICULO Y/O ADYUVANTE FARMACEUTICAMENTE ACEPTABLE, SIENDO UTIL EN EL TRATAMIENTO DE LA DEPRESION, LOS TRASTORNOS DE ANSIEDAD, EL TRASTORNO BIPOLAR, ENTRE OTROS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169217 | 2011-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140934A1 true PE20140934A1 (es) | 2014-08-06 |
Family
ID=46298390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002748A PE20140934A1 (es) | 2011-06-09 | 2012-06-06 | Derivados de pirazol |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9073911B2 (es) |
| EP (1) | EP2717873B1 (es) |
| JP (1) | JP5914642B2 (es) |
| KR (1) | KR101574905B1 (es) |
| CN (1) | CN103596567B (es) |
| AR (1) | AR088741A1 (es) |
| AU (1) | AU2012266457B2 (es) |
| BR (1) | BR112013031324B1 (es) |
| CA (1) | CA2837255C (es) |
| CL (1) | CL2013003484A1 (es) |
| CO (1) | CO6801764A2 (es) |
| CY (1) | CY1116778T1 (es) |
| DK (1) | DK2717873T3 (es) |
| EA (1) | EA024648B1 (es) |
| EC (1) | ECSP13013072A (es) |
| ES (1) | ES2546438T3 (es) |
| HR (1) | HRP20151077T1 (es) |
| IL (1) | IL229549B (es) |
| MA (1) | MA35192B1 (es) |
| MX (1) | MX347239B (es) |
| MY (1) | MY162160A (es) |
| PE (1) | PE20140934A1 (es) |
| PH (1) | PH12013502315A1 (es) |
| PL (1) | PL2717873T3 (es) |
| PT (1) | PT2717873E (es) |
| RS (1) | RS54183B1 (es) |
| SG (1) | SG195156A1 (es) |
| SI (1) | SI2717873T1 (es) |
| TW (1) | TWI440636B (es) |
| UA (1) | UA110525C2 (es) |
| WO (1) | WO2012168260A1 (es) |
| ZA (1) | ZA201308939B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| BR112014015832A8 (pt) | 2012-01-12 | 2017-07-04 | Hoffmann La Roche | derivados heterocíclicos como receptores associados com aminas vistigiais (taars) |
| PT2895477T (pt) * | 2012-09-14 | 2017-12-29 | Hoffmann La Roche | Derivados de pirazol carboxamida como moduladores taar para uso no tratamento de vários distúrbios, como depressão, diabetes e doença de parkinson. |
| WO2014088983A1 (en) * | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| RS60825B1 (sr) | 2016-03-17 | 2020-10-30 | Hoffmann La Roche | Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a |
| EP3615513B1 (en) | 2017-04-24 | 2022-07-20 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| CN112480079B (zh) * | 2017-11-08 | 2022-03-11 | 北京嘉林药业股份有限公司 | 化合物及其治疗癌症的用途 |
| WO2019243964A1 (en) * | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors |
| KR102161787B1 (ko) * | 2018-07-02 | 2020-10-06 | 한국기초과학지원연구원 | 수면 장애의 예방 또는 치료용 약학적 조성물 |
| JP2022501401A (ja) | 2018-09-27 | 2022-01-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の治療のためのヘテロシクリル化合物 |
| KR102396602B1 (ko) * | 2019-02-28 | 2022-05-11 | 주식회사 마더스제약 | 피라졸 아마이드 유도체 화합물 및 이의 용도 |
| BR112021023030A2 (pt) * | 2019-05-14 | 2022-01-04 | Metabomed Ltd | Compostos inibidores de acss2 e métodos de uso dos mesmos |
| EP3997085A1 (en) * | 2019-07-11 | 2022-05-18 | F. Hoffmann-La Roche AG | Process for the preparation of substituted pyrazole derivatives |
| US20240400577A1 (en) * | 2021-07-08 | 2024-12-05 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
| WO2023183444A1 (en) * | 2022-03-24 | 2023-09-28 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
| JP2025526086A (ja) * | 2022-08-12 | 2025-08-07 | エフ． ホフマン－ラ ロシュ アーゲー | ５－エチル－４－メチル－ｎ－［４－［（２ｓ）モルホリン－２－イル］フェニル］－１ｈ－ピラゾール－３－カルボキサミドを含む医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| WO1999028300A1 (en) | 1997-12-04 | 1999-06-10 | Allergan Sales, Inc. | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
| WO2008098857A1 (en) | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| CN102899314A (zh) | 2011-07-29 | 2013-01-30 | 江汉大学 | 一种批量基因克隆的方法 |
-
2012
- 2012-06-01 US US13/485,969 patent/US9073911B2/en active Active
- 2012-06-06 PE PE2013002748A patent/PE20140934A1/es active IP Right Grant
- 2012-06-06 DK DK12727632.7T patent/DK2717873T3/en active
- 2012-06-06 ES ES12727632.7T patent/ES2546438T3/es active Active
- 2012-06-06 TW TW101120350A patent/TWI440636B/zh not_active IP Right Cessation
- 2012-06-06 UA UAA201400123A patent/UA110525C2/ru unknown
- 2012-06-06 EA EA201391787A patent/EA024648B1/ru not_active IP Right Cessation
- 2012-06-06 WO PCT/EP2012/060627 patent/WO2012168260A1/en not_active Ceased
- 2012-06-06 CN CN201280027873.0A patent/CN103596567B/zh not_active Expired - Fee Related
- 2012-06-06 MX MX2013013853A patent/MX347239B/es active IP Right Grant
- 2012-06-06 PH PH1/2013/502315A patent/PH12013502315A1/en unknown
- 2012-06-06 EP EP12727632.7A patent/EP2717873B1/en active Active
- 2012-06-06 PT PT127276327T patent/PT2717873E/pt unknown
- 2012-06-06 AU AU2012266457A patent/AU2012266457B2/en not_active Ceased
- 2012-06-06 CA CA2837255A patent/CA2837255C/en active Active
- 2012-06-06 JP JP2014514042A patent/JP5914642B2/ja not_active Expired - Fee Related
- 2012-06-06 SG SG2013087234A patent/SG195156A1/en unknown
- 2012-06-06 SI SI201230279T patent/SI2717873T1/sl unknown
- 2012-06-06 BR BR112013031324-2A patent/BR112013031324B1/pt not_active IP Right Cessation
- 2012-06-06 HR HRP20151077TT patent/HRP20151077T1/hr unknown
- 2012-06-06 MY MYPI2013004400A patent/MY162160A/en unknown
- 2012-06-06 PL PL12727632T patent/PL2717873T3/pl unknown
- 2012-06-06 RS RS20150549A patent/RS54183B1/sr unknown
- 2012-06-06 KR KR1020147000462A patent/KR101574905B1/ko not_active Expired - Fee Related
- 2012-06-07 AR ARP120102009A patent/AR088741A1/es unknown
-
2013
- 2013-10-31 CO CO13258855A patent/CO6801764A2/es active IP Right Grant
- 2013-11-21 IL IL229549A patent/IL229549B/en active IP Right Grant
- 2013-11-27 ZA ZA2013/08939A patent/ZA201308939B/en unknown
- 2013-12-05 CL CL2013003484A patent/CL2013003484A1/es unknown
- 2013-12-09 EC ECSP13013072 patent/ECSP13013072A/es unknown
- 2013-12-18 MA MA36583A patent/MA35192B1/fr unknown
-
2015
- 2015-10-06 CY CY20151100893T patent/CY1116778T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| PE20141681A1 (es) | Inhibidores de btk | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20161064A1 (es) | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| PE20110136A1 (es) | Compuestos organicos | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| PE20160839A1 (es) | Derivados de 4-azaindol | |
| PE20110061A1 (es) | Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina | |
| PE20140868A1 (es) | Antagonistas trpm8 y su uso en tratamientos | |
| PE20091035A1 (es) | Derivados de 2-aminopirimidina | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| PE20110433A1 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
| MX2018014944A (es) | Tratamiento para la enfermedad de parkinson. | |
| AR093042A1 (es) | Derivados de etinilo | |
| PE20081700A1 (es) | Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |